Imaging cognitive decline in Multiple Sclerosis: highlighting the hippocampus and thalamus

Imaging cognitive decline in Multiple Sclerosis: highlighting the hippocampus and thalamus - Imaging cognitive decline in MS: Highlighting the hippocampus and thalamus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33862

Enrollment

140

Registered

2009-01-28

Start date

2009-03-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS Multiple Sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18-65 years - Clinically definite MS (based on Poser criteria, 1983) - Need to meet the safety criteria to undergo an MRI examination

Exclusion criteria

Exclusion criteria: For all participants:;- History of drug abuse - Psychiatric disorders - Claustrophobia - Foreign non MR compatible metal objects in the body - Foreign metal objects in or close to the head;Additionally for the healthy controls: - Neurological disorders;Additionally for the patients: - Other neurological disorders besides MS - Relapse or steroid treatment in the month prior to the investigation

Design outcomes

Primary

Measure	Time frame
More insight will be given to the underlying pathobiology of memory impairment (mainly hippocampus and thalamus) in MS. This will increase our understanding of memory dysfunction and will hopefully improve the prediction regarding patients* cognitive profiles in the clinic. The primary study parameters of this study will be: 1) Differences between brain activation patterns in healthy controls compared to MS patients during a memory- and attention task. What is the role of functional reorganization. 2) The relation between functional measurements (brain activation patterns during a memory- and attention task) and structural measurements (DTI) will be described. 3) The relation between structural and functional neuroimaging results will be related to the clinical performance of patients on memory- and attention tasks.	—

Measure

Time frame

More insight will be given to the underlying pathobiology of memory impairment (mainly hippocampus and thalamus) in MS. This will increase our understanding of memory dysfunction and will hopefully improve the prediction regarding patients* cognitive profiles in the clinic. The primary study parameters of this study will be: 1) Differences between brain activation patterns in healthy controls compared to MS patients during a memory- and attention task. What is the role of functional reorganization. 2) The relation between functional measurements (brain activation patterns during a memory- and attention task) and structural measurements (DTI) will be described. 3) The relation between structural and functional neuroimaging results will be related to the clinical performance of patients on memory- and attention tasks.

—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results